

# Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_ Pathology: \_\_\_\_\_

Stage:  IA  IB  IIA  IIB  IIIA  IIIB  IV  Recurrent

Line of Treatment:  Neoadjuvant/Pre-Op  Adjuvant/Post-Op  First Line  Second Line  Third Line  Third Line+  Maintenance

ECOG Performance Status:  0  1  2  3  4

## Biomarker:

ALK status:  Positive  Negative  Not reported

EGFR:  Mutation  Wild type  Not reported

BRAF:  V600E Mutation  V600K Mutation  Wild type  Not reported

MET amplification:  Positive  Negative  Not reported

RET gene rearrangement:  Absent  Present  Not reported

ROS1 rearrangement:  Positive  Negative  Not reported

## Adjuvant

Carboplatin (Paraplatin) and paclitaxel (Taxol)

Cisplatin (Platinol) and gemcitabine (Gemzar)

Cisplatin (Platinol) and vinorelbine (Navelbine)

## Primary therapy | Locally advanced / Unresectable disease | Stage III

Cisplatin (Platinol) and etoposide (Toposar) with concurrent XRT

Paclitaxel (Taxol) and carboplatin (Paraplatin) with concurrent XRT

## Metastatic disease | ALK positive or ROS1 positive | First line of therapy (1<sup>st</sup> line)

Crizotinib (Xalkori)

## Metastatic disease | EGFR positive | First line of therapy (1<sup>st</sup> line)

Erlotinib (Tarceva)

## Metastatic disease | PD-L1 Expression High (≥50%) | EGFR and ALK negative | First line of therapy (1<sup>st</sup> line) | ECOG Performance Status = 0, 1, 2

Pembrolizumab (Keytruda)

## Metastatic disease | Non-squamous | First line of therapy (1<sup>st</sup> line) | ECOG Performance Status= 0, 1, 2

Carboplatin\* (Paraplatin) and paclitaxel (Taxol)

Carboplatin (Paraplatin), paclitaxel (Taxol) and bevacizumab (Avastin)

Cisplatin\* (Platinol) and gemcitabine (Gemzar)

Cisplatin\* (Platinol) and pemetrexed (Alimta)

\*In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a Pathway option.

\*\* For patients with EGFR T790M mutation

**Note:** Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.



# Lung Cancer: Non-small Cell Lung Cancer (NSCLC) Pathways (Continued)

## Metastatic disease | Squamous | First line of therapy (1<sup>st</sup> line) | ECOG Performance Status = 0, 1, 2

- \_\_ Carboplatin\* (Paraplatin) and paclitaxel (Taxol)
- \_\_ Cisplatin\* (Platinol) and gemcitabine (Gemzar)

## Metastatic disease | Non-squamous | Maintenance | ECOG Performance Status = 0, 1, 2

- \_\_ Continuation bevacizumab (Avastin)
- \_\_ Continuation pemetrexed (Alimta)
- \_\_ Switch pemetrexed (Alimta)

## Metastatic disease | EGFR T790M mutation | Second line (2<sup>nd</sup> line) after targeted 1<sup>st</sup> line therapy

- \_\_ Osimertinib (Tagrisso) \*\*

## Metastatic disease | ALK positive or EGFR positive | Second or subsequent lines of therapy (2<sup>nd</sup> line +) | ECOG Performance Status = 0, 1, 2

- \_\_ Carboplatin\* (Paraplatin) and paclitaxel (Taxol)
- \_\_ Cisplatin\* (Platinol) and gemcitabine (Gemzar)
- \_\_ Cisplatin\* (Platinol) and pemetrexed (Alimta)

## Metastatic disease | Second or subsequent lines of therapy (2<sup>nd</sup> line+)| ECOG Performance Status = 0, 1, 2

- \_\_ Atezolizumab (Tecentriq)
- \_\_ Nivolumab (Opdivo) (any histology/pathology)
- \_\_ Pemetrexed (Alimta) (Non-Squamous histology/pathology)

## Metastatic disease | EGFR positive | ECOG Performance Status = 3, 4

- \_\_ Erlotinib (Tarceva)

\*In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a Pathway option.

\*\* For patients with EGFR T790M mutation

**Note:** Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

